Physician profile
Theodore J Ware
NPI 1003800145
$1,155.08
in general payments reported to CMS, 2019-2025
21 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $65.30 · 2022: $514 · 2023: $576.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $576.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $575.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $201.15 | 2022-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $138.56 | 2022-2023 | |
| Novartis Pharmaceuticals Corporation | $130.86 | 2019-2023 | |
| Novo Nordisk INC | $120.27 | 2019-2023 | Wegovy, Rybelsus, Ozempic |
| Janssen Pharmaceuticals, INC | $88.36 | 2022-2023 | Spravato |
| Glaxosmithkline, LLC. | $56.99 | 2023 | Trelegy Ellipta, Shingrix |
| Astrazeneca Pharmaceuticals LP | $48.41 | 2022-2023 | Lokelma |
| Lilly USA, LLC | $43.41 | 2023 | Mounjaro |
| Mylan Specialty L.P. | $39.11 | 2022-2023 | Yupelri |
| Dexcom, INC. | $38.91 | 2022-2023 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $34.97 | 2023 | Gemtesa |
| Lundbeck LLC | $29.30 | 2023 | Rexulti |
| Axsome Therapeutics, INC. | $28.52 | 2022-2023 | Sunosi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $25.39 | 2022-2023 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $24.73 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exact Sciences Corporation | $20.69 | 2023 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $20.37 | 2022 | |
| Amgen INC. | $19.16 | 2022 | |
| Astellas Pharma US INC | $18.83 | 2022 | |
| Abbvie INC. | $14.27 | 2023 | Vraylar |
| Evoke Pharma, INC. | $12.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Theodore Ware listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.